Nicox SA / Marinomed GmbH
Exclusive Financial Advisor in the acquisition of Marinomed GmbH, a Biotechnology company developping anti-viral and immunological treatments, including Carragelose® anti-viral eye drop program.
Advised Nicox SA in their acquisition of the Austrian Specialty Ophthalmics Biotechnology Player Marinomed specialized in anti-viral, anti-bacterial, anti-microbial and anti-infective eye-protection treatments, which provided access to the anti-viral program of Carregelose, for € 5.3m based on an all-share deal paid via an ad-hoc share capital increase of Nicox.